David A. Siegel Karuna Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$161.33 - $204.36 $14.3 Million - $18.2 Million	-88,900 Reduced 97.26%	2,500 $454,000
Q4 2022 Feb 14, 2023	BUY	$191.53 - $236.82 $3.2 Million - $3.95 Million	16,700 Added 22.36%	91,400 $18 Million
Q3 2022 Nov 14, 2022	BUY	$123.79 - $277.42 $9.25 Million - $20.7 Million	74,700 New	74,700 $16.8 Million
Q2 2022 Aug 15, 2022	SELL	$93.97 - $143.33 $216,131 - $329,659	-2,300 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$98.9 - $132.37 $39,560 - $52,948	400 Added 21.05%	2,300 $292,000
Q4 2021 Feb 14, 2022	SELL	$110.64 - $159.4 $88,512 - $127,520	-800 Reduced 29.63%	1,900 $249,000
Q3 2021 Nov 15, 2021	BUY	$101.2 - $125.87 $10,120 - $12,587	100 Added 3.85%	2,700 $330,000
Q2 2021 Aug 16, 2021	SELL	$107.45 - $135.95 $75,215 - $95,164	-700 Reduced 21.21%	2,600 $296,000
Q1 2021 May 17, 2021	SELL	$95.46 - $133.08 $238,649 - $332,700	-2,500 Reduced 43.1%	3,300 $397,000
Q4 2020 Feb 16, 2021	BUY	$75.23 - $109.23 $436,334 - $633,534	5,800 New	5,800 $589,000
Q1 2020 May 15, 2020	SELL	$60.41 - $115.92 $211,435 - $405,720	-3,500 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$11.44 - $123.99 $40,040 - $433,965	3,500 New	3,500 $264,000

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.